Application effects of Trastuzumab combined with neoadjuvant chemotherapy in patients with breast cancer
Objective:To explore application effects of Trastuzumab combined with neoadjuvant chemotherapy in patients with breast cancer.Methods:A prospective study was conducted on 100 patients with breast cancer admitted to the hospital from January 2022 to June 2023.According to the random number table method,they were divided into control group and observation group,50 cases in each group.The control group was treated with neoadjuvant chemotherapy(Docetaxel+Carboplatin),while the observation group was treated with Trastuzumab on the basis of those of the control group.The objective response rate(ORR),the serum tumor markers[carbohydrate antigen 15-3(CA15-3),cytokeratin 19 fragment(CYFRA21-1),carcinoembryonic antigen(CEA),vascular endothelial growth factor(VEGF)]levels before and after the treatment,the quality of life[functional assessment of cancer therapy-breast(FACT-B)]scores,and the incidence of adverse reactions were compared between the two groups.Results:The ORR of the observation group was 70.00%(35/50),which was higher than 46.00%(23/50)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of CA15-3,CYFRA21-1,CEA and VEGF in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the FACT-B scores of the two groups were higher than those before the treatment,that in the observation group was higher than that in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of complications such as nausea,vomiting,thrombocytopenia,oral ulcer,abnormal liver function,cardiotoxicity and hand-foot syndrome between the two groups(P>0.05).Conclusions:Trastuzumab combined with neoadjuvant chemotherapy can improve the ORR and the quality of life scores,and reduce the serum tumor marker levels in the patients with breast cancer.Moreover,it is superior to simple neoadjuvant chemotherapy.
Breast cancerTrastuzumabNeoadjuvant chemotherapyTumor markerQuality of lifeAdverse reaction
万方数据
维普
